metastatic colorectal cancer
Conditions
Interventions
Case series:Nil
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Male or female aged = 18 years; 2) Colonoscopy, surgery or other pathological biopsy to diagnose as colorectal adenocarcinoma; 3) CT or MRI or B-ultrasonography or PET/CT or other imaging tests was diagnosed as local or distant organ recurrence or metastasis (liver metastasis, lung metastasis, or hepatic metastasis); 4) Molecular detection of tumor lesions identified as KRAS/NRAS/BRAF/PIK3CA mutations positive; 5) Subjects will undergo radical surgery (surgical removal of primary and metastatic lesions) after surgical evaluation; 6) Subjects have no other serious disease that conflicts with this study; 7) Subject agrees to participate in this trial and has signed an informed consent.
Exclusion criteria
Exclusion criteria: 1) Colonoscopy or surgery or other pathological biopsy diagnose as colorectal neuroendocrine tumors; 2) Diagnosis as nonmetastatic colorectal cancer; 3) Fail to acquire tumor lesion KRAS,NRAS,BRAF,PI3KCA mutation status or mutation status is negative; 4) Other complications that lead to radical resection unavailable; 5) Subjects who participated in other clinical trials within 4 weeks before enrollment; 6) Subjects with tumor recurrence within 3 months after surgery; 7) Subjects who has serious complications after surgery that cannot be followed by subsequent treatment; 8) Subjects who had blood transfusion or other blood products within one month; 9) Subjects who has adverse reactions above CTC-AE2 in preoperative conversion therapy or neoadjuvant treatment that did not return to grade 1; 10) Subjects who cannot participate in this study for other reasons; 11) Subjects who's compliance is insufficient or may not follow the follow-up procedure; 12) Subjects have diseases that interfere with the study: such as mental illness or drug abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Allelic frequency of ctDNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| levels of serum biomarkers; | — |
Countries
China
Contacts
Public ContactWei Guo
Zhongshan Hospital, Fudan University
Outcome results
None listed